This article was originally published in Start Up
Implantable Devices; Artificial Retina. Optobionics is developing an artificial silicon retina that may make use of remaining viable retinal circuitry to transmit visual signals to the brain. The technology is based on microphotodiodes that are implanteed into the eye either arrayed on a small silicon chip, within a biocompatible gel sheet placed in the subretinal space, or injected under the retina mxied with a gelatinous slurry. The microphotodiodes convert light energy to electrical energy.
You may also be interested in...
A mere seven years ago, before the approval of Visudyne photodynamic therapy, patients losing their vision to age-related macular degeneration (AMD) were told that there was nothing that could be done for them. Today, AMD sufferers may choose from an assortment of drug treatments. Genentech's Lucentis will reach almost $1 billion in sales in its first year on the market, analysts predict, and it doesn't claim to do anything except slow down the progression of the disease. Moreover, the drug does this better than first-generation anti-VEGF drug Macugen. And if those options aren't enough--and they're not--a handful of start-ups developing device-based therapies are making significant progress by applying some highly innovative approaches. ScyFIX, for example, is applying electrical stimulation to halt the effects of AMD and possibly repair the damage done. NeoVista is applying radiation therapy to the back of the eye, an approach that could serve as an alternative to Lucentis and other drugs based on growth factors, which require frequent injections into the eye. Retina Implant has developed an implantable microchip that will stimulate intact nerve cells in the retina to recreate the sense of sight.
Intelligent Medical Implants is one of a select group of companies, along with Optobionics and Second Sight Medical Products, developing a retinal implant. It sees itself as the leader, having implanted the first completely wireless retinal prosthesis in four patients with more than six months of follow-up.
Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.